Policy Statement

The use of a multibiomarker disease activity score for rheumatoid arthritis (RA) (e.g., Vectra® DA score) is considered investigational in all situations.

Policy Guidelines

There is a specific CPT code for this test:

- **81490**: Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score

Description

Assessment of disease activity in rheumatoid arthritis is an important component of management with a goal of treatment being to maintain low disease activity or achieve remission. There are a variety of instruments for measuring rheumatoid arthritis disease activity. The instruments use combinations of physical exam findings, radiologic results, and serum biomarkers to construct a disease activity score. A multibiomarker disease activity instrument is a disease activity measure that is comprised entirely of serum biomarkers. The Vectra DA test is a commercially available multibiomarker disease activity blood test that uses 12 biomarkers to construct a disease activity score ranging from 1 (low disease activity) to 100 (high disease activity).

Related Policies

- N/A

Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

Regulatory Status

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. The Vectra® DA test (Crescendo Bioscience) is available under the auspices of Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.
Rationale

Background
Rheumatoid Arthritis

Rheumatoid arthritis (RA) is characterized by chronic joint inflammation leading to painful symptoms, progressive joint destruction, and loss of function. The disorder is relatively common and associated with a high burden of morbidity for affected patients.

Treatment

Treatment of RA has undergone a shift from symptom management to a more proactive strategy of minimizing disease activity and delaying disease progression. The goal of treatment is to reduce the irreversible joint damage that occurs from ongoing joint inflammation and synovitis by keeping disease activity as low as possible. The availability of an increasing number of effective disease-modifying antirheumatic drugs has made the achievement of remission, or sustained low disease activity, a feasible goal for a large proportion of patients with RA. This treatment strategy has been called a tight control approach.

The concept of tight control in the management of RA has gained wide acceptance. Evidence from clinical trials has demonstrated that outcomes are improved with a tight control strategy, in which treatment targets are mainly based on measures of disease activity. In a systematic review, Schoels et al (2010) identified 7 studies that evaluated the efficacy of tight control. Four of these trials randomized patients to tight control using treatment targets or to routine management, 2 studies compared different treatment targets, and 1 study compared results from a targeted treatment with historical controls. The treatment targets were heterogeneous, including symptom-based measures, joint scores on the exam, validated treatment activity measures, lab values, or combinations of these factors. In all 4 trials that randomized patients to tight control or routine management, there was a significant decrease in the Disease Activity Score (DAS) or its 28 joints version (DAS28) and in the likelihood of achieving remission for patients in the tight control group.

According to American College of Rheumatology (ACR) guidelines, initial treatment of patients with RA is monotherapy (usually a disease-modifying antirheumatic drug). Treatment may progress to combination therapy if disease activity remains moderate or high despite monotherapy. Combination therapy may consist of additional disease-modifying antirheumatic drugs or the addition of tumor necrosis factors or non-tumor necrosis factors biologics.

Validated Disease Activity Assessment Tools

For a strategy of tight control to be successful, a reliable and valid measurement of disease activity is necessary. There are numerous disease activity measurements that can be used in clinical care.

Through a 5-stage process that included review by an expert advisory panel in RA disease activity and detailed evaluation of psychometric properties, an ACR working group determined that 6 measures were accurate reflections of disease activity: Clinical Disease Activity Index (CDAI), DAS28, Patient Activity Scale, Patient Activity Scale II, Routine Assessment of Patient Index Data 3, and the Simplified Disease Activity Index (SDAI).

Two systematic reviews were published the same year as the ACR’s recommendations, one by Gaujoux-Viala et al (2012) and the other by Salaffi et al (2012), which compared disease activity measures for patients with RA. Results from the systematic reviews were consistent with the ACR working group recommendations, citing the DAS28, SDAI, and CDAI as appropriate disease activity measures for RA.

Table 1 summarizes the clinical and laboratory measurements included in each of the 6 disease activity measures recommended by ACR. The table also includes the laboratory measures...
included in the Vectra DA, a multi-biomarker disease activity (MBDA) test which currently does not have a recommendation from ACR.

### Table 1. Clinical and Laboratory Components of Rheumatoid Arthritis Disease Activity Measurements

<table>
<thead>
<tr>
<th>DAS28</th>
<th>CDAI and SDAI</th>
<th>PAS</th>
<th>PAS II</th>
<th>RAPID3</th>
<th>Vectra DA</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of swollen joints out of 28&lt;sup&gt;a&lt;/sup&gt;</td>
<td>No. of swollen joints out of 28&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Patient describes ability to do each of 20 activities as “without any difficulty,” “with some difficulty,” “with much difficulty,” or “unable to do”</td>
<td>Patient describes ability to do each of 10 activities as “without any difficulty,” “with some difficulty,” “with much difficulty,” or “unable to do”</td>
<td>Patient describes ability to do each of 13 activities as “without any difficulty,” “with some difficulty,” “with much difficulty,” or “unable to do”</td>
<td>Interleukin-6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No ACR Recommendation</th>
<th>Tumor necrosis factor receptor type I</th>
</tr>
</thead>
</table>

| No. of tender joints out of 28<sup>a</sup> | No. of tender joints out of 28<sup>a</sup> | Patient indicates need for cane, crutches, walker, wheelchair, or devices to assist with dressing or eating | Patient rates pain on scale of 0 (no pain) to 10 (severe pain) | Patient rates pain on scale of 0 (no pain) to 10 (severe pain) |

| ESR (mm/h) | CRP (mg/L) (only in the SDAI, not part of CDAI calculation) | Patient indicates need for assistance in dressing, rising, eating, walking, hygiene, reaching, gripping, or chores | Patient rates how they are doing on scale of 0 (very well) to 10 (very poor) | Patient rates how they are doing on scale of 0 (very well) to 10 (very poor) |

| CRP (mg/L) | Patient Global Assessment (0 [very well] to 10 [very poor]) | Patient indicates if special devices needed in bathroom or kitchen | Patient rates pain on scale of 0 (no pain) to 10 (severe pain) |

| Patient Global Assessment (0 [best] to 100 [worst]) | Physician Global Assessment (0 [very well] to 10 [very poor]) | Patient rates pain on scale of 0 (no pain) to 10 (severe pain) |

| Patient rates how they are doing on scale of 0 (very well) to 10 (very poor) | Patient rates how they are doing on scale of 0 (very well) to 10 (very poor) |

Adapted by Anderson et al (2012).<sup>4</sup>

ACR: American College of Rheumatology; CDAI: Clinical Disease Activity Index; CRP: C-reactive protein; DAS28: Disease Activity Score 28; ESR: erythrocyte sedimentation rate; MMP: matrix metalloproteinase; PAS: Patient Activity Scale; RAPID3: Routine Assessment of Patient Index Data 3; SDAI: Simplified Disease Activity Index.

<sup>a</sup> Twenty-eight joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees.

<sup>b</sup> Dress self; shampoo hair; stand from chair; get in and out of bed; cut meat; bring cup to mouth; open milk carton; walk outdoors on flat ground; climb 5 steps; wash and dry body; take tub bath; get on and off toilet; reach and bring down 5 pound object from above head; bend and pick up clothing from floor; open car door; open new jar; turn faucets on and off; run errands; get in and out of car; do chores (e.g., vacuum or yard work).

<sup>c</sup> Stand from chair; walk outdoors on flat ground; get on and off toilet; reach and bring down 5 pound object from above head; open car door; do outside work such as yard work; wait in line for 15 minutes; lift heavy objects; move heavy objects; climb 2 or more flights of stairs.

<sup>d</sup> Dress self; get in and out of bed; bring cup to mouth; walk outdoors on flat ground; wash and dry body; bend and pick up clothing from floor; turn faucets on and off; get in and out of car; walk 2 miles; participate in recreational activities; sleep well; deal with feelings of anxiety or nervousness; deal with feelings of depression or sadness.
**Vectra DA Test**

The manufacturer describes Vectra DA as a complement to clinical judgment. Although not explicitly stated, it appears that the test may be used as an adjunct to other disease activity measures, to potentially identify patients at high risk of progression who would, therefore, benefit from a more aggressive treatment strategy.

The Vectra DA test scores range from 1 to 100. Categories of scores were constructed to correlate with the DAS28-CRP scale:

- 45-100: high disease activity
- 30-44: moderate disease activity
- 1-29: low disease activity.

**Literature Review**

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

**Vectra DA Testing For Disease Activity in Rheumatoid Arthritis**

**Clinical Context and Test Purpose**

The purpose of the MBDA, specifically the Vectra DA, in patients who have rheumatoid arthritis (RA) is to determine the level of disease activity (low, medium, or high) in order to inform treatment decisions.

The question addressed in this evidence review is: Does use of a MBDA (e.g., Vectra DA) test, alone or as an adjunct, to predict disease activity in patients with RA, improve health outcomes compared with use of American College of Rheumatology (ACR)–recommended measures of disease activity?

The following PICOTS were used to select literature to inform this review.

**Patients**

The relevant population of interest is individuals with RA who are being managed with a disease-modifying antirheumatic drug (DMARD).

Management of patients with RA has changed from treatment of symptoms to a tight control strategy. The objective of a tight control strategy is to minimize disease progression and joint damage by monitoring disease activity and treating aggressively if an increase in activity is predicted.

**Interventions**

Vectra DA provides a score indicating the level of disease activity, based on blood levels of the following 12 biomarkers: interleukin-6, tumor necrosis factor (TNF) receptor type I, vascular cell adhesion molecule 1, epidermal growth factor, vascular endothelial growth factor A, YKL-40 glycoprotein, matrix metalloproteinase 1, matrix metalloproteinase 3, C-reactive protein (CRP), serum amyloid A, leptin, and resistin.

Scores range from 1 to 100 (1-29=low disease activity; 30-44=medium disease activity; 45-100=high disease activity).
Comparators
The reference standard for disease activity is radiographic progression at a set point in time, typically 3 months to 1 year. In addition, an ACR expert panel on RA determined the following 6 disease activity measures were useful and feasible to implement in a clinical setting: Clinical Disease Activity Index (CDAI), Disease Activity Score with 28 joints (DAS28), Patient Activity Scale, Patient Activity Scale II, Routine Assessment of Patient Index Data 3, and Simplified Disease Activity Index.

Outcomes
The goal of treating patients with RA is to improve quality of life and to prevent progression of the disease. Progression of disease causes irreversible joint damage.

If Vectra DA correctly assesses disease activity as low, the clinician may maintain medications at the same level or consider tapering the patient’s medication.

If Vectra DA correctly assesses disease activity as moderate or high, the clinician may be more aggressive in disease management, by either increasing doses of current medications, switching medications, or adding medications to the treatment plan.

If Vectra DA incorrectly assesses disease activity as low, the clinician may maintain or decrease medication levels, which will allow progression of the disease and further joint damage.

If Vectra DA incorrectly assesses disease activity as moderate or high, the clinician may continue to manage the patient with higher levels of medication than is necessary to prevent disease progression, exposing the patient to unnecessary toxins. DMARDs may affect the liver, stomach, and intestines. Biologic agents may increase the risk of infection, lymphoma, and skin cancer.

Timing
The test may be run as often as a clinician needs disease activity information, typically every 3 to 6 months. A test immediately after diagnosis may serve as a baseline measurement.

For purposes of assessing Vectra DA against the reference standard of radiographic progression, 1 year is the typical time frame.

Setting
The test may be given at an outpatient rheumatology practice or an academic or community setting. Primary care may be the main source of care in some locations.

Study Selection Criteria
For the evaluation of the clinical utility of a multibiomarker disease activity test (e.g., Vectra DA), studies would need to use the test as either an adjunct or a replacement to current disease activity measures to manage treatment decisions in patients with RA. Outcomes would be quality of life and measures of disease progression.

In the absence of direct evidence for the clinical utility of Vectra DA, evidence for clinical validity is evaluated, in which we can make inferences on clinical utility. For the evaluation of clinical validity, studies would need to compare Vectra DA used as an adjunct or as a replacement to ACR-recommended disease activity measures, with radiographic progression as a reference standard. Key validity outcomes of sensitivity, specificity, as well as positive (PPV) and negative (NPV) predictive values, should be reported.
**Technically Reliable**
Assessment of technical reliability focuses on specific tests and operators and requires review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review, and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

**Clinically Valid**
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

All evidence identified used the Vectra DA test. Eleven publications using data and serum samples from 8 studies met selection criteria and are included in this review. Table 2 summarizes study characteristics of the publications:

- Six studies (8 publications) included records and archived samples from randomized controlled trials (RCTs).9-16
- One study (2 publications) included records and samples from a cohort study.17,18
- One study included records and samples from a single-arm study.19
- One study (2 publications) used random (weighted) samples; the remaining were convenience samples.17,18
- All studies were retrospective analyses. Prospective protocols precluding the inference that these were nonconcurrent prospective studies could not be identified (as described by Simon et al [2009]20).
- Reference standard for most studies was radiographic progression, generally at 1 year. The definition of radiographic progression varied among studies. Some studies also included moderate radiographic progression and rapid radiographic progression.
- Eight publications used thresholds of low (<30), moderate (30–44), and high (>44). One study used a threshold of remission (≤25) or no remission (>25). Two publications analyzed Vectra as a continuous score.
- Outcome assessment was blinded in 3 publications, with no report on blinding of assessors in the remaining 8 publications.

Table 3 provides clinical validity results for the studies. Below are select key points from the results:

- Samples included in the publications ranged from 52 to 524 patients.
- Only 1 publication reported sensitivity and specificity data. Hambardzumyan et al (2015) reported that the sensitivity for high Vectra risk was 98%, specificity was 17%, NPV was 97%, and PPV was 21%.11 The low specificity and PPV do not support the use of the test to “rule in” high-risk disease.
- Four studies reported area under the receiver operating characteristic curve (AUROC) data, and another reported positive likelihood ratios. Seven publications reported the percentage of patients progressing by Vectra class.
- In 2 publications, the AUROC for the Vectra test was numerically higher than the DAS28; however, the confidence intervals overlapped.10,18 Overlapping confidence intervals indicate uncertainty whether Vectra DA provides prognostic performance superior to DAS28.
- In 3 studies,9,13,15 Vectra scores were not associated with radiographic progression or rapid radiographic progression, and in another,19 Vectra correlated with radiographic progression at 1 time point (26 weeks), but not at baseline or 1 year.
- One study reported a higher positive likelihood ratio for Vectra compared with DAS28, again with overlapping confidence intervals.17
- One study reported that significantly more patients with low Vectra scores responded to triple therapy compared with anti-TNF therapy, while significantly more patients with high Vectra scores responded to anti-TNF therapy compared with triple therapy.16
Table 2. Study Characteristics of Included Studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Population</th>
<th>Design</th>
<th>Reference Standard (Time From Test to RP)</th>
<th>Threshold for Positive Index Test</th>
<th>Blinding of Assessors</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bakker et al (2012)</td>
<td>CAMERA, early RA</td>
<td>Retrospective; convenience</td>
<td>RP at 2 y</td>
<td>NA: Continuous scores used in analysis</td>
<td>NR</td>
<td>Patients randomized to intensive or conventional treatment</td>
</tr>
<tr>
<td>Van der Helm-van Mil et al (2013)</td>
<td>Leiden EAC cohort with symptoms &lt;2 y; samples collected between 1995 and 2005</td>
<td>Retrospective; random (weighted sample)</td>
<td>Moderate RP and RRP at 1 y</td>
<td>Remission (≤25) vs not remission (&gt;25)</td>
<td>Yes</td>
<td>Infrequent use of anti-TNFs in this population</td>
</tr>
<tr>
<td>Markusse et al (2014)</td>
<td>BeST patients with symptoms &lt;2 y</td>
<td>Retrospective; convenience</td>
<td>RP and RRP after 1 y</td>
<td>NA: Continuous scores used in analysis</td>
<td>NR</td>
<td>Same samples as Hirata et al (2013)</td>
</tr>
<tr>
<td>Hambardzumyan et al (2015)</td>
<td>SWEFOT, DMARD-naive</td>
<td>Retrospective; convenience</td>
<td>RRP at 1 y</td>
<td>Low (&lt;30), moderate (30-44), and high (&gt;44)</td>
<td>NR</td>
<td>Patients treatment with MTX until 3 mo, nonresponders randomized to MTX plus triple therapy or MTX plus infliximab</td>
</tr>
<tr>
<td>Hambardzumyan et al (2016)</td>
<td>SWEFOT, DMARD-naive</td>
<td>Retrospective; convenience</td>
<td>RRP at 2 y</td>
<td>Low (&lt;30), moderate (30-44), and high (&gt;44)</td>
<td>NR</td>
<td>Overlapping samples with Hambardzumyan et al (2015); does not explain the differing n's</td>
</tr>
<tr>
<td>Fleischmann et al (2016)</td>
<td>AMPLEx, biologic-naive, RA ≤5 y, inadequate response to MTX</td>
<td>Retrospective; convenience</td>
<td>RP at 1 y</td>
<td>Low (&lt;30), moderate (30-44), and high (&gt;44)</td>
<td>Yes</td>
<td>Patients randomized to MTX plus abatacept or MTX plus adalimumab</td>
</tr>
<tr>
<td>Li et al (2016)</td>
<td>Leiden EAC cohort with symptoms &lt;2 y; samples collected between 1995 and 2005</td>
<td>Retrospective; random (weighted sample)</td>
<td>Moderate RP and RRP at 1 y</td>
<td>Low (&lt;30), moderate (30-44), and high (&gt;44)</td>
<td>NR</td>
<td>Overlap with van der Helm et al (2013)</td>
</tr>
<tr>
<td>Hirata et al (2016)</td>
<td>Patients treated with TNF inhibitor for ≥1 y at a single institution</td>
<td>Retrospective; convenience</td>
<td>Clinically relevant RP; RRP at 1 y</td>
<td>Low (&lt;30), moderate (30-44), and high (&gt;44)</td>
<td>Yes</td>
<td>Overlap with Hirata et al (2015)</td>
</tr>
<tr>
<td>Bouman et al (2017)</td>
<td>DRESS, RCT of tapering TNF inhibitors until discontinuation or flaring vs usual care</td>
<td>Retrospective; convenience</td>
<td>RP at 18 mo</td>
<td>Low (&lt;30), moderate (30-44), and high (&gt;44)</td>
<td>NR</td>
<td>Flare defined as increase in DAS28-CRP &gt; 1.2 vs baseline or increase in DAS28-CRP &gt; 0.6 vs baseline plus current DAS28 ≥ 3.2</td>
</tr>
<tr>
<td>Hambardzumyan et al (2017)</td>
<td>SWEFOT, inadequate responders to MTX at 3 mo</td>
<td>Retrospective, convenience</td>
<td>EULAR criteria for response to treatment</td>
<td>Low (&lt;30), moderate (30-44), and high (&gt;44)</td>
<td>NR</td>
<td>May overlap with Hambardzumyan et al (2015)</td>
</tr>
<tr>
<td>Krabbe et al (2017)</td>
<td>Patients treated with TNF inhibitor for 1 y at a single institution</td>
<td>Retrospective, single arm</td>
<td>RP at 1 y</td>
<td>Remission (≤25), low (26-29), moderate (30-44), and high &gt;44</td>
<td>NR</td>
<td>RP defined by MRI synovitis, MRI bone marrow edema, US synovial PD score; and US GSS</td>
</tr>
</tbody>
</table>

AMPLE: Abatacept versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate; BeST: Behandel Strategieën; CAMERA: Computer Assisted Management in Early Rheumatoid Arthritis; CRP: C-reactive protein; DAS28: Disease Activity Score with 28 joints; DMARD: disease-modifying antirheumatic drug; DRESS: Dose REduction Strategies of Subcutaneous TNF Inhibitors trial; EAC: Early Arthritis Clinic; EULAR: European League Against Rheumatism; GSS: grey scale synovitis; MR: magnetic resonance imaging; MTX: methotrexate; NA: not applicable; NR: not reported; PD: power Doppler; RA: rheumatoid arthritis; RCT: randomized controlled trial; RP: radiographic progression; RRP: rapid radiographic progression; SWEFOT: Swedish Farmacotherapy; TNF: tumor necrosis factor; US: ultrasound.
### Table 3. Clinical Validity Results for the Vectra DA Test

<table>
<thead>
<tr>
<th>Study</th>
<th>Initial N</th>
<th>Final N</th>
<th>Excluded Samples</th>
<th>Prevalence of Condition</th>
<th>Clinical Validity: Risk Outcome, %</th>
<th>Other Reported Measures (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bakker et al (2012)⁹</td>
<td>NR for CAMERA</td>
<td>120 samples (72 at BL, 48 at 6 mo), not clear if overlapping samples</td>
<td>Serum unavailable</td>
<td>NR</td>
<td>NR</td>
<td>Vectra: BL or 6 mo not associated with RP in multivariate analyses</td>
</tr>
<tr>
<td>Van der Helm-van Mil et al (2013)¹⁷</td>
<td>NR</td>
<td>163 patients (271 samples)</td>
<td>Not selected by sampling</td>
<td>Moderate</td>
<td>Vectra: 7%⁶  DAS28: 20%⁶</td>
<td>Vectra PLR=4.7 (1.7 to 15.0) DAS28 PLR=1.4 (0.9 to 2.4)</td>
</tr>
<tr>
<td>Markusse et al (2014)¹⁰</td>
<td>508 in BeST</td>
<td>125 (91 at BL; 89 at 1 y); 84 with BL serum and 1-y radiograph</td>
<td>Missing or insufficient samples</td>
<td>RP=37%</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Hambardzumyan et al (2015)¹¹</td>
<td>487 in SWEFOT</td>
<td>235 with complete BL demographic, serologic, radiographic, and clinical data</td>
<td>Incomplete data</td>
<td>RRP=18%</td>
<td>Vectra: 0% DAS28: NA</td>
<td></td>
</tr>
<tr>
<td>Hambardzumyan et al (2016)¹²</td>
<td>487 in SWEFOT</td>
<td>220 patients with Vectra DA scores, CRP, ESR, and DAS28 at BL, 205 at 3 mo, 133 at 1 y</td>
<td>Incomplete data</td>
<td>RRP=30%</td>
<td>Vectra: 3 mo: 9% DAS28: 6%</td>
<td></td>
</tr>
<tr>
<td>Fleischmann et al (2016)¹³</td>
<td>646 in AMPLE</td>
<td>524 with available data</td>
<td>Unavailable data</td>
<td>RP=30%</td>
<td>Vectra: 3 mo: 26% DAS28: 15%</td>
<td></td>
</tr>
<tr>
<td>Li et al (2016)¹⁸</td>
<td>NR</td>
<td>163 patients (271 samples)</td>
<td>Not selected by weighted sampling</td>
<td>Mod RP=26% RRP=17%</td>
<td>Vectra mod: 3 mo: 19% DAS28: 20%</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Initial N</td>
<td>Final N</td>
<td>Excluded Samples</td>
<td>Prevalence of Condition</td>
<td>Clinical Validity: Risk Outcome, %</td>
<td>Other Reported Measures (95% CI)</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------</td>
<td>---------</td>
<td>---------------------------------------</td>
<td>-------------------------</td>
<td>-----------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>Hirata et al (2016)</td>
<td>NR</td>
<td>83</td>
<td>Patients without data at 24 wk</td>
<td>Clinically relevant RP=12%</td>
<td>• Vectra: 0% • Vectra: 4% • Vectra: 28%</td>
<td>AUROC RRP=0.66 (0.56 to 0.75)</td>
</tr>
<tr>
<td>Bouman et al (2017)</td>
<td>171</td>
<td>167</td>
<td>Patients without both serum samples and 18-mo radiographs</td>
<td>RP=26%</td>
<td>• RP occurred in 31% in the dose-tapering group and in 16% in the usual care group</td>
<td>AUROC tapering: 0.53 (0.41 to 0.66)</td>
</tr>
<tr>
<td>Hambardzumyan et al (2017)</td>
<td>157</td>
<td>157</td>
<td>No exclusions</td>
<td>Responders to triple therapy 47% and responders to anti-TNF therapy was 54%</td>
<td>19 responded to triple therapy (88%) more than to anti-TNF therapy (18% p=0.006)</td>
<td>AUROC flare: 0.50 (0.41 to 0.59)</td>
</tr>
<tr>
<td>Krabbe et al (2017)</td>
<td>52</td>
<td>52</td>
<td>Patients with missing data</td>
<td>RP=19%</td>
<td>In 10 with disease progression, 0 had low Vectra score</td>
<td>Vectra correlated poorly with MRI/US at BL and 52 wk; Vectra correlated well with MRI/US at 26 wk</td>
</tr>
</tbody>
</table>

ABA: abatacept; ADM: adalimumab; AMPLE: Abatacept versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate; AUC: area under the curve; BeST: Behandel Strategieën; BL: baseline; CAMERA: Computer Assisted Management in Early Rheumatoid Arthritis; BL: baseline; CRP: C-reactive protein; CDAI: Clinical Disease Activity Index; DAS28: 28-joint Disease Activity Score; ESR: erythrocyte sedimentation rate; MBDA: multibiomarker disease activity; Mod: moderate; MRI: magnetic resonance imaging; NA: not available; NPV: negative predictive value; NR: not reported; PLR: positive likelihood ratio; PPV: positive predictive value; RP: radiographic progression; RRP: rapid radiographic progression; SWEFOT: Swedish Farmacotherapy; TNF: tumor necrosis factor; US: ultrasound.

a Estimated from figure.
b “Low” risk is remission and “high” risk is not remission.
### Gaps Assessment for Clinical Validity

The purpose of the gaps tables (see Tables 4 and 5) is to display notable gaps identified in each study. This information is synthesized as a summary of the body of evidence following each table and provides the conclusions on the sufficiency of evidence supporting the position statement.

#### Table 4. Relevance Gaps for the Validity Studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcomes</th>
<th>Duration of FU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bakker et al (2012)</td>
<td></td>
<td>3. Not consistent with current use, which is as an adjunct to other disease activity measures</td>
<td></td>
<td>3. Key clinical validity outcomes not reported (sensitivity, specificity, predictive values); only AUROC reported</td>
<td></td>
</tr>
<tr>
<td>Van der Helm-van Mil et al (2013)</td>
<td></td>
<td>3. Not consistent with current use, which is as an adjunct to other disease activity measures</td>
<td></td>
<td>3. Key clinical validity outcomes not reported (sensitivity, specificity, predictive values); risk of remission reported</td>
<td></td>
</tr>
<tr>
<td>Markusse et al (2014)</td>
<td></td>
<td>3. Not consistent with current use, which is as an adjunct to other disease activity measures</td>
<td></td>
<td>3. Key clinical validity outcomes not reported (sensitivity, specificity, predictive values); only AUROC reported</td>
<td></td>
</tr>
<tr>
<td>Hambardzumy an et al (2015)</td>
<td></td>
<td>3. Not consistent with current use, which is as an adjunct to other disease activity measures</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hambardzumy an et al (2016)</td>
<td></td>
<td>3. Not consistent with current use, which is as an adjunct to other disease activity measures</td>
<td></td>
<td>3. Key clinical validity outcomes not reported (sensitivity, specificity, predictive values); comparisons to other biomarkers reported</td>
<td></td>
</tr>
<tr>
<td>Fleischmann et al (2016)</td>
<td></td>
<td>3. Not consistent with current use, which is as an adjunct to other disease activity measures</td>
<td></td>
<td>3. Key clinical validity outcomes not reported (sensitivity, specificity, predictive values); correlations with other biomarkers reported</td>
<td></td>
</tr>
<tr>
<td>Li et al (2016)</td>
<td></td>
<td>3. Not consistent with current use, which is as an adjunct to other disease activity measures</td>
<td></td>
<td>3. Key clinical validity outcomes not reported (sensitivity, specificity, predictive values); correlations with radiographic progression reported</td>
<td></td>
</tr>
<tr>
<td>Hirata et al (2016)</td>
<td></td>
<td>3. Not consistent with current use, which is as an adjunct to other disease activity measures</td>
<td></td>
<td>3. Key clinical validity outcomes not reported (sensitivity, specificity, predictive values); correlations with radiographic progression reported</td>
<td></td>
</tr>
<tr>
<td>Bouman et al (2017)</td>
<td></td>
<td>3. Not consistent with current use, which is as an adjunct to other disease activity measures</td>
<td></td>
<td>3. Key clinical validity outcomes not reported (sensitivity, specificity, predictive values); AUROC reported</td>
<td></td>
</tr>
</tbody>
</table>
The evidence gaps stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

AUROC: area under the receiver operating curve; DAS28: Disease Activity Score with 28 joints; FU: follow-up.

a Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.
b Intervention key: 1. Classification thresholds not defined; 2. Version used unclear; 3. Not intervention of interest.
c Comparator key: 1. Classification thresholds not defined; 2. Not compared to credible reference standard; 3. Not compared to other tests in use for same purpose.
d Outcomes key: 1. Study does not directly assess a key health outcome; 2. Evidence chain or decision model not explicated; 3. Key clinical validity outcomes not reported (sensitivity, specificity and predictive values); 4. Reclassification of diagnostic or risk categories not reported; 5. Adverse events of the test not described (excluding minor discomforts and inconvenience of venipuncture or noninvasive tests).
e Follow-Up key: 1. Follow-up duration not sufficient with respect to natural history of disease (true positives, true negatives, false positives, false negatives cannot be determined).

Table 5. Study Design and Conduct Gaps for the Validity Studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Selectiona</th>
<th>Blindingb</th>
<th>Delivery of Testc</th>
<th>Selective Reportingd</th>
<th>Data Completenesse</th>
<th>Statisticalf</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bakker et al (2012)⁹</td>
<td>2. Selection not random or consecutive; convenience serum samples from an RCT</td>
<td>1. Blinding of assessors not reported</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Van der Helm-van Mil et al (2013)¹⁷</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Markusse et al (2014)¹⁰</td>
<td>2. Selection not random or consecutive; convenience serum samples from an RCT</td>
<td>1. Blinding of assessors not reported</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hambardzumyan et al (2015)¹¹</td>
<td>2. Selection not random or consecutive; convenience serum samples from an RCT</td>
<td>1. Blinding of assessors not reported</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hambardzumyan et al (2016)¹²</td>
<td>2. Selection not random or consecutive; convenience serum samples from an RCT</td>
<td>1. Blinding of assessors not reported</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Selection</td>
<td>Blinding</td>
<td>Delivery of Test</td>
<td>Selective Reporting</td>
<td>Data Completeness</td>
<td>Statistical</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------</td>
<td>----------</td>
<td>------------------</td>
<td>---------------------</td>
<td>-------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Fleischmann et al (2016)</td>
<td>2. Selection not random or consecutive; convenience serum samples from an RCT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2. No statistical test reported to compare MBDA vs alternatives, only tests comparing treatment groups</td>
</tr>
<tr>
<td>Li et al (2016)</td>
<td></td>
<td></td>
<td></td>
<td>1. Blinding of assessors not reported</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hirata et al (2016)</td>
<td>2. Selection not random or consecutive; convenience serum samples from an RCT</td>
<td></td>
<td></td>
<td>1. Blinding of assessors not reported</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bouman et al (2017)</td>
<td>2. Selection not random or consecutive; convenience serum samples from an RCT</td>
<td></td>
<td></td>
<td>1. Blinding of assessors not reported</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hambardzumyan et al (2017)</td>
<td>2. Selection not described; single-arm study with no explanation of how patients recruited</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Krabbe et al (2017)</td>
<td>2. Selection not described; single-arm study with no explanation of how patients recruited</td>
<td></td>
<td>1. Blinding of assessors not reported</td>
<td>4. Expertise of evaluators not described</td>
<td>3. High loss of follow-up: 14% at 20 wk and 30% at 50 wk</td>
<td>1. P values only reported for some comparisons</td>
</tr>
</tbody>
</table>

The evidence gaps stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

FU: follow-up; MBDA: multibiomarker disease activity; RCT: randomized controlled trial.

- **Selection key:** 1. Selection not described; 2. Selection not random or consecutive (i.e., convenience).
- **Blinding key:** 1. Not blinded to results of reference or other comparator tests.
- **Delivery of Test key:** 1. Timing of delivery of index or reference test not described; 2. Timing of index and comparator tests not same; 3. Procedure for interpreting tests not described; 4. Expertise of evaluators not described.
- **Selective Reporting key:** 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.
- **Data Completeness key:** 1. Inadequate description of indeterminate and missing samples; 2. High number of samples excluded; 3. High loss to follow-up or missing data.
- **Statistical key:** 1. Confidence intervals and/or p values not reported; 2. Comparison to other tests not reported.

**Subsection Summary: Gaps Assessment for Clinical Validity**

Limitations in the body of evidence for clinical validity are identified in Tables 4 and 5. Relating to the relevance of the studies, only 1 of the 9 studies calculated sensitivity, specificity, and positive and negative predictive values. Most reported area under the curve measures and/or correlations with other disease activity measures. None evaluated MBDA as an adjunct to other disease activity measures, which is how the MBDA is currently being marketed.
The study design and conduct gaps table shows that 8 studies used convenience samples of serum from RCTs and one was a single-arm study with no explanation of how patients were recruited or enrolled. Eight studies did not report whether the radiographic assessors were blinded to the biomarker results.

**Section Summary: Clinically Valid**

Evidence for the clinical validity of the MBDA test consists of analyses of archived serum samples from RCTs as well as prospective cohort studies that have correlated MBDA with other measures of disease activity and with radiographic progression. Results from studies comparing MBDA with other disease activity measures have shown a positive correlation; however, results from studies comparing MBDA with radiographic progression are inconsistent. Only 1 study reported sensitivity and specificity, with a PPV of 21%, indicating that 4 out of 5 patients identified as positive would receive intensification of therapy unnecessarily.

Currently, MBDA is used as an adjunct to other disease activity measures. No evidence was identified that evaluated the incremental benefit of MBDA when used as an adjunct to other disease activity measures.

Overall, studies lacked reporting of sensitivity, specificity, and predictive values, which are the most informative measures for ascertaining the performance of Vectra DA in selecting high-risk patients for intensification of therapy. The evidence is insufficient to conclude the clinical validity of Vectra DA compared with ACR-recommended measures of disease activity.

**Clinically Useful**

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

**Direct Evidence**

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

To demonstrate clinical utility, there should be evidence that the MBDA score is at least as good a measure of disease activity as other available measures or that the MBDA score demonstrates an incremental benefit when used as an adjunct with other disease activity measures. To demonstrate equivalence with other measures directly, an RCT comparing health outcomes of 2 groups, 1 group managed using the Vectra DA test and the other group managed by another disease activity measure is needed.

To directly demonstrate an incremental benefit when used as an adjunct, an RCT should compare health outcomes in patients receiving treatment guided by MBDA plus a disease activity measure with outcomes in patients receiving treatment guided only by the other disease activity measure.

**Chain of Evidence**

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility. Because there is insufficient evidence that the MBDA score is clinically valid, direct evidence is needed to prove clinical utility. No trials were identified that provided direct evidence of clinical utility.
Section Summary: Clinically Useful
There are no RCTs comparing the use of the Vectra DA score with an alternative method of measuring disease activity. Additionally, there are no RCTs of Vectra DA as an adjunct to other disease activity measures compared with using the disease activity measures alone. Absent direct evidence for clinical utility, a chain of evidence could be constructed with indirect evidence proving clinical validity. However, there is insufficient evidence that MBDA is clinically valid.

Summary of Evidence
For individuals who have rheumatoid arthritis who receive a MBDA (e.g., Vectra DA) test as an adjunct or as a replacement of other disease activity measures, the evidence includes analyses of archived serum samples from RCTs and prospective cohort studies. Relevant outcomes are test validity, other test performance measures, symptoms, change in disease status, functional outcomes, and quality of life. Analyses comparing Vectra DA with other previously validated disease activity measures such as the DAS28 or to radiographic progression, consisted mostly of correlations, with only 1 study providing sensitivity, specificity, and positive and negative predictive values. The positive predictive value from this study was 21%. Other analyses of archived serum samples evaluated the use of Vectra DA to predict treatment response. Results from those analyses were inconsistent. The body of evidence on the Vectra DA test is insufficient to determine whether it is as good as or better than other disease activity measures. Additionally, there is no evidence evaluating Vectra DA as an adjunct to other disease activity measures. The evidence is insufficient to determine the effects of the technology on health outcomes.

Supplemental Information
Practice Guidelines and Position Statements
American College of Rheumatology
In its 2015 guidelines on the treatment of rheumatoid arthritis, the American College of Rheumatology endorsed the following measures of disease activity: Patient Activity Scale, Routine Assessment of Patient Index Data 3, Clinical Disease Activity Index, Disease Activity Score with 28 joints, and Simplified Disease Activity Index.3 The guidelines indicated that other measures are available to clinicians, but that including the new measures was out of scope.

European League Against Rheumatism
The European League Against Rheumatism (2017) updated its guidelines on the management of early arthritis.23 The League recommended that arthritis activity be assessed at 1- to 3-month intervals to determine target treatment. “Monitoring of disease activity should include tender and swollen joint counts, patient and physician global assessments, erythrocyte sedimentation rate, and C reactive protein, usually by applying a composite measure.” Composite measures recommended include the Disease Activity Score with 28 joints, Clinical Disease Activity Index, and Simplified Disease Activity Index. One item on the research agenda recommended by the League was to evaluate new biomarkers and multibiomarkers for the prognosis and treatment in early arthritis.

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
There are no Medicare national coverage determinations for the Vectra DA test. In July 2013, Palmetto GBA, the Medicare contractor in California, issued a coverage decision for the Vectra DA test.24 Because all Vectra DA tests are processed out of the Crescendo Bioscience Laboratory in California, the test will be covered for Medicare patients in the United States.

Ongoing and Unpublished Clinical Trials
A currently ongoing trial that might influence this review is listed in Table 6.
### Table 6. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02832297a</td>
<td>Prospective Outcomes Study: Vectra® DA Guided Care Compared to Usual Care</td>
<td>318</td>
<td>Aug 2018</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.
a Denotes industry-sponsored or cosponsored trial.

### References


**Documentation for Clinical Review**

- No records required

**Coding**

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy. Inclusion or exclusion of codes does not constitute or imply member coverage or provider reimbursement.

IE

The following services may be considered investigational.

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT®</td>
<td>81490</td>
<td>Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score</td>
</tr>
</tbody>
</table>
### Definitions of Decision Determinations

**Medically Necessary:** A treatment, procedure, or drug is medically necessary only when it has been established as safe and effective for the particular symptoms or diagnosis, is not investigational or experimental, is not being provided primarily for the convenience of the patient or the provider, and is provided at the most appropriate level to treat the condition.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

### Prior Authorization Requirements (as applicable to your plan)

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department. Please call (800) 541-6652 or visit the provider portal at www.blueshieldca.com/provider.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.